What Atrophy, Hypertrophy, and Cardiac Failure Have in Common

Donghoon Lee, Alfred Goldberg

Proteins in cardiac and skeletal muscle cells, as in other cells, are continually being synthesized and degraded back to their constituent amino acids. Protein turnover in cardiac myocytes utilizes the same proteolytic systems as other eukaryotic cells: the ubiquitin-proteasome pathway, which catalyzes the rapid degradation of misfolded and regulatory proteins, and the lysosomal-autophagic system, which degrades organelles and aggregated proteins. These systems are of major importance in determining cardiac size and functional capacity. The overall rates of proteolysis in a cell and the degradation of individual components are precisely regulated. For example, cardiac hypertrophy occurs when overall rates of protein synthesis exceed overall rates of protein degradation; conversely cells decrease in mass when degradation rates exceed synthesis, as occurs in skeletal muscle with disuse, fasting, and many systemic diseases, including cardiac failure. In addition, the levels of individual proteins, whether they are enzymes, transcription factors, or components of the sarcomere, are determined in large part by their rates of ubiquitin-mediated degradation. In this issue of Circulation Research, Usui et al demonstrate how a single ubiquitination enzyme can have major effects on cardiac growth and function.

In this pathway, proteins are targeted for degradation by the 26S proteasome by covalent attachment of a chain of ubiquitin molecules. This multistep pathway first involves the activation of the small protein ubiquitin by an enzyme, E1, which then transfers the highly reactive ubiquitin to one of the cell’s many ubiquitin-conjugating enzymes, E2s. A ubiquitin-protein ligase, E3, then binds the protein substrate and the ubiquitin-E2 and catalyzes the formation of a chain of ubiquitins on the protein. Different E2-E3 pairs function in the degradation of different proteins, and the specificity of the E3s for specific groups of proteins provides exquisite selectivity to this degradation process. The content of different E2s and E3s varies between tissues and with different physiological conditions (as is nicely illustrated by the findings of Usui et al), but which E2s and E3s function normally in cardiac muscle is unknown. The human genome contains over 650 ubiquitin ligases, which makes possible precise regulation of different cell processes, and in recent years, dramatic progress has been made in elucidating the roles of different E3s in regulating metabolism, transcription, cell cycle, oncogenesis, and so forth. Although the pharmacological modulation of specific ubiquitin ligases is an attractive approach for treating many diseases, this possibility has thus far not been exploited, although an inhibitor of the proteasome (Bortezomib) is now widely used in the treatment for certain hematologic cancers.

In this regard, it is intriguing that proteasome inhibitors also attenuate or reverse cardiac hypertrophy in multiple rodent models.

Atrogin1, Also Known as MAFbx, Is Critical for Skeletal Muscle Atrophy and Cardiac Hypertrophy

The article by Usui et al has uncovered an important, unexpected role of the ubiquitin ligase Atrogin1/MAFbx in cardiac hypertrophy. Their finding is particularly surprising because this E3 has been shown to be crucial in skeletal muscle atrophy. In fact, because of its dramatic induction in nearly all forms of muscle atrophy, its expression is widely used as a marker of muscle wasting (especially when accompanied by induction of another atrophy-related ubiquitin ligase, MuRF1). In studies to identify the key mechanisms driving muscle atrophy, about 100 genes were identified that were named atrophy-related genes or atrogenes, whose expression was induced or suppressed similarly in rodent muscles undergoing various types of atrophy, including fasting, untreated diabetes, renal failure, acidosis, cancer cachexia, and denervation or disuse. They were therefore named “atrogenes,” for atrophy-related genes. Among this set of genes, Atrogin1/MAFbx was one of the most dramatically induced. It is a muscle-specific E3, present also in cardiac and smooth muscle, although in fasting and catabolic disease, it is induced specifically in skeletal muscles, where proteolysis increases to provide the stressed organism with a supply of amino acids for gluconeogenesis and adaptive responses. A similar induction has been observed in muscles of patients with trauma, sepsis, and renal failure, in which there is marked muscle wasting. In experimental models, induction of Atrogin1 mRNA accompanies the rapid atrophy; that is, within 1 to 3 days after cutting the motor neuron, its level rises maximally and then falls after 14 days back to control level. Thus, high levels of this protein coincide with and help trigger the rapid weight loss.

This gene contains an F-box, a hallmark of a large family of multicomponent ubiquitin ligases. The F-box protein is the substrate-binding subunit that functions in a larger complex together with 3 other subunits (Skp1, Rbx1, and Cullin1) that also function with other F-box proteins in the ubiquitination...
of other proteins. This ubiquitin ligase was discovered simultaneously by Goldberg’s laboratory, who named it Atrogin1 because of its dramatic induction in diverse types of atrophy, and by Glass and Yancopoulos’s group, who named it MAFbx, because it was a muscle F-box protein. Both names, though widely used, now seem inappropriate because a number of other muscle F-box proteins are now known and because it is not specific to atrophy, as shown by Usui et al. They report that Atrogin1/MAFbx is also induced during compensatory hypertrophy of the heart, where it is important for the large increase in cardiac mass after aortic constriction and especially for the growth of cardiac myocytes induced with phenylephrine. In fact, had the present studies appeared 11 years ago, Atrogin1 might have been named Hypertrogin1. Moreover, this E3 appears to contribute particularly to the development or pathological hypertrophy and cardiac failure because MAFbx-knockout animals showed a mild reduction in hypertrophy and a large decrease in various pathological sequelae such as pulmonary congestion and fibrosis and cardiomyocyte apoptosis. This surprising induction in hypertrophy is consistent with the prior finding that its level decreases during cardiac atrophy induced by unloading.

Such a dual role in hypertrophy and atrophy is indeed surprising because these processes have opposite consequences and appear to involve quite different signaling mechanisms. Muscle hypertrophy proceeds through increased activity of the PI3K-AKT-FoxO pathway, which enhances protein synthesis and suppresses proteolysis, whereas in atrophy, these two enzymes appear to promote the breakdown of different cell proteins; for example, MuRF1 alone does not cause muscle atrophy, the accelerated degradation of eIF3-f should certainly reduce hypertrophy. Although overexpression of MAFbx in mice alone does not cause muscle atrophy, the accelerated degradation of eIF3-f reduced myotube size. Thus, although overexpression of MAFbx in mice alone does not cause muscle atrophy, the accelerated degradation of eIF3-f reduced myotube size. Thus, although overexpression of MAFbx in mice alone does not cause muscle atrophy, the accelerated degradation of eIF3-f should certainly reduce growth capacity. Whether a similar effect on eIF3-f occurs on Atrogin1 induction during cardiac hypertrophy is an interesting and important issue that was not addressed by Usui et al. In the heart, Atrogin1 also ubiquitinates and reduces the levels of calcineurin A, which is an important factor triggering cardiac hypertrophy in response to pressure overload. In cardiac myocytes, overproduction of Atrogin1 also inhibits phenylephrine-induced hypertrophy by decreasing calcineurin A levels. The finding that Atrogin1 degrades proteins primarily involved in growth is clearly difficult to reconcile with this protein’s newly discovered role in promoting hypertrophy, although it could be important in the induction of cardiac failure.

**Regulation of Atrogin1/MAFbx Expression**

In skeletal muscle, the expression of Atrogin1 and MuRF1 are tightly regulated and rise in response to diverse stimuli that promote muscle wasting, including low insulin states,
glucocorticoids, acidosis, inactivity, and myostatin. These catabolic stimuli all activate the FoxO family of transcription factors, which mediate transcription of many atrogens, including Atrogin1, MuRF1, and many genes for autophagy. Consequently, activated FoxO3 by itself induces profound atrophy of skeletal and cardiac muscles.\(^5\)\(^,\)\(^15\) Conversely, activated FoxO3 by itself induces profound atrophy of skeletal and cardiac muscles.\(^5\)\(^,\)\(^15\) Consequently, atrophy of skeletal and cardiac muscles.\(^5\)\(^,\)\(^15\) These two actions together promote protein synthesis, and by inactivating FoxOs reduce proteolysis.\(^16\)\(^,\)\(^17\) These two actions together promote protein synthesis, and by inactivating FoxOs reduce proteolysis.\(^16\)\(^,\)\(^17\) These two actions together synergize to cause rapid hypertrophy. In addition, the exercise-induced transcription cofactor PGC-1\(\alpha\), which promotes production of mitochondria, also inhibits the activation of FoxO3, and this action helps explain the capacity of exercise to prevent muscle atrophy.\(^18\) Despite its importance in regulating Atrogin1 and MuRF1 in catabolic conditions (including cardiac myocytes deprived of growth factors), FoxO3 was not found by Usui et al to be activated during cardiac hypertrophy when Atrogin1 was induced. Thus, it is highly likely that an as-yet unidentified transcription factor responds to pressure overload and catecholamines to trigger transcription of MAFbx. Therefore, the mechanisms signaling Atrogin1 (MAFbx) induction in atrophy and hypertrophy appear to be fundamentally different, although the differences observed thus far might still be explained by differences between heart and skeletal muscles. So, analogous studies of compensatory hypertrophy in skeletal muscle appear important to clarify whether they also express Atrogin1 in response to increased load by a FoxO-independent mechanism.

Initially, hearts of mice lacking Atrogin1/MAFbx were reported to exhibit no clear abnormality\(^6\); however, their ability to respond to physiological challenges had not been tested until Usui et al made the important finding that Atrogin1/MAFbx is required for maximal hypertrophy, and especially for its pathological consequences (ie, increase in lung congestion, apoptosis of myocardial cells, and decreased left ventricular production of lethal myosis). Among the important, unexpected findings in this report was that deletion of Atrogin1/MAFbx decreased the degradation of I\(\kappa\)B\(\alpha\), the inhibitor of nuclear factor (NF)-\(\kappa\)B, which is the transcription factor triggering many pathological responses. Conversely, overexpression of Atrogin1/MAFbx promoted the degradation of I\(\kappa\)B\(\alpha\) and activation of NF-\(\kappa\)B. In other cells, these responses are the hallmarks of inflammation and production of inflammatory mediators. In hypertrophied heart, NF-\(\kappa\)B had been previously found to rise, and the discovery that Atrogin1/MAFbx ubiquitinates I\(\kappa\)B\(\alpha\) and thereby is a positive regulator of cardiac NF-\(\kappa\)B is an important discovery whose physiological and pathological consequences remain to be defined. In skeletal muscle, NF-\(\kappa\)B is necessary for atrophy and is activated together with FoxOs when Atrogin1/MAFbx is induced.\(^19\) Perhaps Atrogin1/MAFbx helps trigger its activation in the atrophying muscles.

**Outstanding Questions**

Puzzling observations and apparent paradoxes in research can be valuable in stimulating additional experimental studies and further progress. Beyond its novel findings, the article by Usui et al raises several perplexing points that certainly merit future in-depth study. Because knockout of Atrogin1/MAFbx diminished hypertrophy, overexpression of this gene would be expected to promote cardiac growth. However, muscle size was decreased by overexpressing MAFbx. Thus, a major puzzle is that both its deletion and overexpression attenuate cardiac hypertrophy. One possible explanation could be that Atrogin1/MAFbx plays a specific role in an initial step promoting hypertrophy (eg, degradation of I\(\kappa\)B\(\alpha\)), but, subsequently, when Atrogin1/MAFbx levels markedly increase, it may then attenuate muscle growth, as these authors found on its overexpression, and as Atrogin1/MAFbx does in atrophying muscles. Perhaps there are distinct substrates for this E3 in the early and later phases, where pathological consequences and failure become evident that may also result from the buildup of NF-\(\kappa\)B.

Based on the apparent importance of NF-\(\kappa\)B in hypertrophying hearts and in multiple other diseases, it will be illuminating to define its precise effects on cardiac size and function—specifically to learn whether selective downregulation of NF-\(\kappa\)B diminishes hypertrophy or overexpression of NF-\(\kappa\)B can increase heart size and failure. Such studies could have therapeutic applications because inhibitors of NF-\(\kappa\)B are available for clinical study. In skeletal muscle, this transcription factor synergizes with FoxOs in promoting overall proteolysis and atrophy, which should not be of benefit in a compromised heart. Probably, the best studied function of NF-\(\kappa\)B in disease is in enhancing the production of inflammatory mediators, including interleukin-1, tumor necrosis factor-\(\alpha\), and interleukin-6, which was found to increase in these hypertrophied hearts by a MAFbx-dependent mechanism. These potent mediators appear to be likely contributors to the development of pathological hypertrophy and cardiac failure. However, another important action of NF-\(\kappa\)B in most cells, and especially in many cancers, is in reducing apoptosis. Such an effect in cardiac hypertrophy appears to be likely because it would account for the finding of Usui et al of less apoptosis and less production of the NF-\(\kappa\)B-dependent anti-apoptotic mediator Bcl-3 in hearts of mice lacking MAFbx. Such effects would be expected to protect myocytes and be beneficial. Thus, NF-\(\kappa\)B activation can have both toxic and helpful consequences in the overloaded heart. Finally, these observations emphasize the importance of identifying the major transcription factor triggering Atrogin1/MAFbx expression because it clearly plays a crucial role in cardiac disease and because it is neither FoxO3 nor NF-\(\kappa\)B. Moreover, this unknown factor and its activation mechanisms would be very attractive new therapeutic targets.

**Disclosures**

None.

**References**


Atrogin1/MAFbx: What Atrophy, Hypertrophy, and Cardiac Failure Have in Common
Donghoon Lee and Alfred Goldberg

doi: 10.1161/CIRCRESAHA.111.248872

*Circulation Research* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/109/2/123

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation Research* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

**Reprints:** Information about reprints can be found online at:
http://www.lww.com/reprints

**Subscriptions:** Information about subscribing to *Circulation Research* is online at:
http://circres.ahajournals.org//subscriptions/